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Attachment of nanoparticles (NPs) to the surface of carrier red blood cells (RBCs) profoundly alters 
their interactions with the host organism, decelerating NP clearance from the bloodstream while 
enabling NP transfer from the RBC surface to the vascular cells. These changes in pharmacokinetics 
of NPs imposed by carrier RBCs are favorable for many drug delivery purposes. On the other hand, 
understanding effects of NPs on the carrier RBCs is vital for successful translation of this novel drug 
delivery paradigm. Here, using two types of distinct nanoparticles (polystyrene (PSNP) and lysozyme-
dextran nanogels (LDNG)) we assessed potential adverse and sensitizing effects of surface adsorption 
of NPs on mouse and human RBCs. At similar NP loadings (approx. 50 particles per RBC), adsorption 
of PSNPs, but not LDNGs, induces RBCs agglutination and sensitizes RBCs to damage by osmotic, 
mechanical and oxidative stress. PSNPs, but not LDNGs, increase RBC stiffening and surface exposure 
of phosphatidylserine, both known to accelerate RBC clearance in vivo. Therefore, NP properties 
and loading amounts have a profound impact on RBCs. Furthermore, LDNGs appear conducive to 
nanoparticle drug delivery using carrier RBCs.
Optimizing pharmacokinetics (PK) is an important element of design of vascular drug delivery systems1–3. A 
number of methods have been developed to prolong circulation time of nanocarriers/nanoparticles (NPs) and 
avoid uptake by the reticuloendothelial system (RES), such as PEG surface coatings, modification of NP shape 
(e.g. elongated), and increased mechanical flexibility of NPs4–25. More recently, improved circulation time was 
achieved through the adsorption of NPs onto the surface of red blood cells (RBCs)21,22,26–32.
The attempts to coopt RBCs, natural carriers for many endogenous compounds, to carry drugs span several 
decades33–36. RBCs, the most abundant cellular constituent of the blood (>99%), have many features of ideal drug 
carriers, including their bioavailability, biocompatibility, and longevity in circulation (approximately 45 days in 
mice and 120 days in humans). Beyond prolonging an adsorbed NP’s lifetime in the bloodstream, RBCs offer 
mechanisms for masking attached cargo compounds by the glycocalyx37–40 and for cargo delivery to vascular 
targets including thrombi, immune cells, macrophages, endothelial cells, and the RES sinuses41–44.
There have been many studies investigating blood-biomaterial interactions. Foreign materials that interact 
with bodily components such as platelets and RBCs can provoke complement activation, inflammation, and 
thrombosis45. Platelet activation and aggregation can be induced by different materials, such as TiO2, in the pres-
ence of Ca2+, collagen, fibronectin, and poly-L-lysine46,47. For RBCs, detrimental interactions such as aggregation, 
crenation, and hemolysis suggest incompatibility. Previous studies showed that non-covalent adsorption of rigid 
polymeric NPs (200 nm polystyrene spherical beads used as model drug delivery vehicles) to naive mouse RBCs 
altered the behavior of the resultant RBC-NP complexes upon intravenous administration in naive mice. The 
circulation time of RBC-bound NPs was remarkably longer than that of free NPs. Importantly, adsorption of NPs 
onto RBCs at ratios up to 50:1 did not accelerate elimination of the carrier RBC29. Furthermore, RBC adsorp-
tion enabled the transfer of reversibly associated NPs to the pulmonary vasculature29. More recently, and more 
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comforting in translational terms, it was reported that human RBCs are generally less fragile and more resistant 
to adverse effects of NPs than mouse RBCs48. This previous body of work leveraged the use of a model NP type, 
and the results strongly suggests that attachment of NPs to the surface of RBCs can lead to many advantages in 
NP drug delivery.
However, little is known about changes caused to RBCs by NPs, as a result of either intentional adsorption 
on RBCs or unintentional interactions. The RBC plasma membrane is characterized by a unique combination of 
high mechanical flexibility necessary to squeeze through the microvasculature, and physical sturdiness needed 
to survive high hydrodynamic stresses in circulation, especially in the heart and aorta49–52. Senescent, infected 
(e.g., by malaria plasmodium), genetically impaired (e.g., in sickle cell disease), or artificially modified RBCs 
are not as resistant to damaging factors, leading to membrane disruption and release of the RBC’s main protein 
cargo, hemoglobin48,52–62. Previous studies have indicated that adsorption of NPs onto murine RBCs is not overtly 
detrimental for short periods of time (<8 h) and that RBCs tolerate carriage of rigid NPs at loading doses pro-
viding attachment of up to an average of about 50 NP per RBC in vitro without inducing hemolysis48. However, 
the adsorption of polystyrene beads onto RBCs at ratios of 50:1 or greater causes their agglutination in vitro48. In 
addition, polystyrene beads have been found to alter membrane structures in molecular stimulations63,64.
In the present study, we aimed to elucidate the role that biomaterial properties have in regulating interactions 
with RBCs. RBC damage induced in vitro by different NPs was assessed using assays developed in our previous 
work48. We have demonstrated that the adsorption of polystyrene beads (PSNP) induces negative effects on RBCs, 
whereas the adsorption of NPs made from soft biodegradable materials, lysozyme-dextran nanogels (LDNGs), 
does not induce negative effects on RBCs, strongly suggesting that NP properties directly relate to biocompati-
bility. LDNGs, composed of biodegradable components with validated in vivo use65,66, have not been extensively 
investigated as a NP for cell-mediated delivery. These results are important and encouraging in the context of both 
understanding how distinct materials interact with RBCs and in the potential utility of LDNGs as a cargo to be 
delivered by RBCs.
Results
Characterization of NPs. Table 1 lists the basic characteristics of the NPs employed in the study. As 
determined by dynamic light scattering, the diameter of PSNP and LDNG was 171 ± 3.0 nm and 268 ± 9.6 nm, 
respectively, whereas the size of their IgG-conjugated counterparts was 239 ± 1.2 nm and 279 ± 3.8 nm, respec-
tively. The NPs showed suitable size distribution, with PDI values of 0.023 and 0.12 for PSNP and LDNG, 
respectively, whereas the PDI values of their IgG-conjugated counterparts was 0.074 and 0.177, respectively. The 
particles exhibited distinct surface charges; the zeta potential was strongly negative for PSNP and close to neu-
tral for LDNG (33.27 ± 1.05 vs −0.42 ± 0.09 mV, respectively). The conjugation of IgG onto PSNP and LDNGs 
increased the zeta potential of both particles (−3.98 ± 0.76 mV vs 0.43 ± 0.16 mV). The larger PSNP had a diam-
eter of 319 ± 1.6 nm (PDI of 0.069) and had a zeta potential that was strongly negative (−54.83 ± 0.23 mV) 
(Supplemental Table 1).
Adsorption of NP to RBC. Table 2 and Fig. 1 quantify binding of radiolabeled NP formulations to washed 
RBCs. Pristine PSNP bound to murine RBCs at 4 times the rate of LDNG particles. This enhanced binding can be 
explained by the differences in surface charge, as shown in Table 1.
Next, we tested whether loading to RBC can be modulated by coating the surface of NPs with IgG, a generic 
model protein widely used as a control in drug delivery applications and also readily encountered in blood. Of 
note, radiolabeled IgG itself didn’t bind substantially to either murine or human RBCs (Table 2); however, con-
jugating NPs with IgG altered NP binding to RBCs. In particular, IgG-conjugated LDNG (IgG-LDNG) bound to 
RBCs at nearly ten times the rate of the non-IgG LDNG counterpart. The effect of IgG conjugation on PSNP prior 
PSNP IgG-PSNP LDNGs IgG-LDNGs
Size (nm) 171.1 ± 3.0 239.0 ± 1.2 268.2 ± 9.6 278.7 ± 3.8
PDI 0.023 ± 0.01 0.074 ± 0.02 0.117 ± 0.02 0.177 ± 0.04
Zeta Potential 
(mV) −33.27 ± 1.05 −3.98 ± 0.76 −0.42 ± 0.09 0.43 ± 0.16
Table 1. Size and charge of unmodified and IgG-Nanoparticles.
Murine RBCs Human RBCs
% Adsorption Efficiency #NP/RBC % Adsorption Efficiency #NP/RBC
PSNP 24.0 ± 1.5 48.0 ± 3.0* NA NA
IgG-PSNP 25.3 ± 5.0 50.5 ± 10.0 26.7 ± 5.7 53.5 ± 11.5
LDNGs 5.1 ± 0.3 10.1 ± 1.0 6.1 ± 2.8 12.2 ± 5.5
IgG-LDNGs 48.5 ± 5.0 84.7 ± 10.0 22.2 ± 2.7 44.3 ± 5.4
IgG alone 0.7 ± 0.1 NA 1.7 ± 0.4 NA
Table 2. Attachment of Nanoparticles to RBC. Adsorption of various nanoparticles were at NP:RBC ratio of 
200:1. *Represents extrapolation via least squares linear regression of number of particles adsorbed onto murine 
RBC, as described in previous work29. NA represents values not assessed.
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to binding to RBC was not as pronounced and exhibited no statistical differences. As a result, murine RBC carried 
approximately 90 NPs per RBC in the case of IgG-LDNG versus approximately 50 NPs per RBC in the case of 
IgG-PSNP. In the case of human RBC, both IgG-LDNG and IgG-PSNP showed similar RBC binding, approaching 
50 particles per cell.
Agglutination of RBC by PSNP and LDNG particles. PSNP of two diameters (~200 nm and ~300 nm), 
incubated with either murine or human RBC at NP:RBC loading ratio of 50:1, cause RBC aggregation. This is 
demonstrated through the use of a standard agglutination assay in U-shaped microwells (Fig. 2, Supplementary 
Fig. S2) and in an independent microscopic examination (Supplemental Fig. S1). In contrast, neither LDNG nor 
IgG-LDNG caused significant RBC agglutination even at 4-fold higher NP:RBC ratios (Fig. 2).
Figure 1. The number of nanoparticles adsorbed onto murine red blood cells. Number of unmodified or IgG 
coated polystyrene beads (PSNP) as well as unmodified or IgG coated lysozyme dextran nanogels (LDNGs) 
adsorbed per murine RBC at NP:RBC loading ratio of 200:1. Values are means (n = 4–7) ± SEM. (***P < 0.001 
vs. unmodified NP). #Represents extrapolation via least squares linear regression of number of particles 
adsorbed onto murine RBC, as described in previous work29.
Figure 2. Agglutination of red blood cells with nanoparticles adsorbed onto their surface. Agglutination was 
visualized using U-shaped wells containing murine and human red blood cells. Treatment of RBCs with dog 
serum was used as a positive control for agglutination.
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Sensitivity of RBC:NP to Osmotic Stress. Next, we tested the effect of NP binding on RBC sensitivity to 
osmotic lysis. Binding of PSNP to murine RBCs aggravates hemolysis in hypotonic NaCl concentrations ranging 
from ~100 to ~50 mM (Fig. 3a) at PSNP:RBC loading ratio of 2000:1, whereas neither LDNG nor IgG-LDNG 
particles caused this effect (Fig. 3b and c). At the rate-limiting osmolality (~75 mM NaCl), the sensitization of 
RBCs to osmotic lysis was detectable at 200 nm PSNP:RBC loading ratios 50:1, 200:1 (~30% lysis vs. ~20% for 
naïve RBCs), and 2000:1 (~75% lysis), while LDNGs did not detectably enhance lysis even at the excessively high 
ratio of 2000:1 (Fig. 3d). Additionally, larger PSNP particles (300 nm diameter) at PSNP:RBC loading ratio of 
2000:1 aggravated osmotic lysis in a similar fashion to 200 nm PSNPs (Supplemental Fig. S2). In accordance with 
previous observations, human RBCs are more resistant to osmotic lysis and therefore neither PSNPs nor LDNGs 
caused significant lysis even at NP:RBC loading ratios of 2000:1 (Supplemental Fig. S3).
Sensitivity of NP-carrying RBC to shear stress. We examined sensitivity of RBCs suspended in isotonic 
solution to prolonged moderate mechanical stress caused by rotation at 24 rpm and 37 °C. As shown in Fig. 4, 
naïve murine RBCs (dashed lines) exhibited low levels of hemolysis at 1 h (4% lysis) and 8 h (7% lysis) rotation. 
Most likely, this effect reflects deleterious changes in RBCs caused by their isolation, energy starvation, and lack 
of the stabilizing effects of normal blood plasma. Within the time intervals (up to 8 hours) at which murine RBCs 
withstood low level shear stresses, PSNP:RBC loading ratios of 200:1 (data not shown) and 50:1 ratios did not 
Figure 3. Osmotic fragility of murine red blood cells with adsorbed nanoparticles. Representative osmotic 
fragility curves for NP:murine RBC at NP:RBC ratio 50:1, 200:1, or 2000:1 immediately after exposure to 
different [NaCl] following adsorption of PSNP (a), LDNGs (b), or IgG-LDNGs (c). Percent hemolysis for 
different NP:RBC ratios at 73 mM NaCl (d). Values are means (n = 4–6) ± SEM. (*P < 0.05; ***P < 0.001 vs 
naïve RBC).
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sensitize RBCs. However, a PSNP:RBC loading ratio of 2000:1 aggravated hemolysis (12% lysis after 1 h; 17% 
lysis after 8 h) under low shear stress conditions. Similar exacerbation of lysis was observed for PSNPs of 200 nm 
and 300 nm diameters (Supplemental Fig. S2). In contrast, LDNGs, both with and without IgG surface coating, 
did not aggravate mechanical lysis of RBCs, even at the highest tested loading level (2000:1 LDNG:RBC loading 
ratio). Qualitatively similar results have been obtained with human RBCs, with the exception that the lysis of 
murine RBC was more extensive than human RBC (Supplemental Fig. S4).
Sensitivity of NP-carrying RBC to oxidative stress. We also assessed the levels of hemolysis induced 
by H2O2 under low levels of hydrodynamic stress, following adsorption of NPs. As shown in Fig. 5, 24 h H2O2 
treatment induced 65% and 88% lysis in RBCs loaded with PSNPs at 50:1 and 2000:1, respectively. Under the 
same conditions, H2O2 induced 53% lysis in naïve RBCs. Unlike PSNPs, adsorption of LDNGs, both with and 
without surface conjugation of IgG, onto murine RBCs at LDNG:RBC ratios as high as 2000:1 did not signifi-
cantly enhance oxidative fragility (58% lysis). We also detected a significant increase in oxidative hemolysis of 
human RBCs following adsorption of PSNPs (~10-fold over naïve RBCs for 2000:1 PSNPs:RBCs loading). Similar 
to the murine result, the adsorption of LDNGs at an LDNG:RBC ratio of 2000:1 did not enhance H2O2-induced 
hemolysis over results with naïve RBCs (Supplemental Fig. S5).
Effect of NPs on RBC Exposure of Phosphatidylserine. These data implied that binding of highly-charged 
PSNP, but not LDNGs, may be detrimental for RBCs at high loading rates. To investigate more specific mecha-
nisms of RBC damage, we determined the effect of NPs on exposure of phosphatidylserine on the surface of the 
RBCs. Phosphatidylserine mediates the physiological mechanism that marks senescent and damaged RBC for 
clearance by the RES.
RBC, PSNP:RBC, LDNG:RBC, and IgG-LDNG:RBC were incubated at room temperature with Annexin V to 
detect phosphatidylserine. The proportion of phosphatidylserine-exposing murine RBCs dramatically increases 
after adsorption of PSNP (Fig. 6). At NP:RBC loading ratio of 200:1, PSNP adsorption onto murine RBCs induced 
an 87% proportion of RBCs expressing phosphatidylserine, compared with 0.1% of naive RBCs and 0.3% of 
RBCs following LDNG adsorption (0.3%). At NP:RBC ratio of 1000:1, the percentage of murine RBCs expressing 
phosphatidylserine was 92% for PSNP loading, compared to 0.3% for LDNG loading. Representative flow cytom-
etry scatter plots of murine RBC and NP:RBC exposing phosphatidylserine are shown in Supplemental Fig. S6. 
Adsorption of PSNP at NP:RBC ratios as low as 200:1 also increased the proportion of human RBCs exposing 
phosphatidylserine, whereas adsorption of LDNG-based particles at loading ratios as high as 1000:1 did not 
(Supplemental Fig. S7).
Effect of bound NPs on RBC deformability. We then used ektacytometry to determine whether or not 
adsorbed NPs affected RBC deformability. In addition to phosphatidylserine exposure, membrane rigidity is a key 
determinant of RBC phagocytosis by the RES67–71. The ability of RBCs to deform is critical for capillary passage 
Figure 4. Fragility of murine red blood cells with adsorbed nanoparticles under continuous low mechanical 
stress: Percent hemolysis for NP:murine RBC ratio of 50:1 or 2000:1 after constant rotation at 37 °C for 8 h. 
Dotted line represents RBCs without NPs under identical treatment. Inset: Percent hemolysis after 1 h rotation 
for NP:murine RBCs. Values are means (n = 5) ± SEM (***P < 0.001 vs naïve RBC under low stress).
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and delivery of oxygen to tissues. Reduced RBC deformability contributes to the pathogenesis of various hemato-
logical disorders that impair flow, and augments RBC retention in the spleen71–78.
Our results indicate that the effect of adsorbed PSNP on murine RBCs resulted in a significant dose-dependent 
decrease in RBC deformability (Fig. 7). The addition of adsorbed PSNP onto RBC at PSNP:RBC ratios as low as 
200:1 resulted in a decrease in the EImax value, reflecting the maximum extent to which an RBC can deform, 
as compared to naïve RBC (0.517 ± 0.008 vs. 0.533 ± 0.003, respectively) (Fig. 7a). PSNP at a high PSNP:RBC 
ratio of 1000:1 resulted in a further decrease in EImax (0.498 ± 0.017) as compared to naïve RBC counterpart 
(0.533 ± 0.003). PSNPs of both 200 nm and 300 nm diameter had significant effects on RBC deformability 
(Supplementary Fig. S2). The adsorption of LDNGs onto murine RBCs at LDNG:RBC loading ratios as high 
Figure 5. Oxidative fragility of murine red blood cells with adsorbed nanoparticles. Percent hemolysis for 
NP:murine RBC ratio of 50:1 and 2000:1 after being challenged with H2O2 under constant rotation for 24 h. 
Dotted line represents naïve RBC treated with H2O2. Inset: Percent hemolysis after NP:RBCs challenged 4 h with 
H2O2. Values are means (n = 4–5) ± SEM. (*P < 0.05; ***P < 0.001 vs naïve RBC treated with 3 mM H2O2).
Figure 6. Expression of phosphatidylserine on murine red blood cells. Percentage of phosphatidylserine-
exposing murine red blood cells after the adsorption of PSNP, LDNG, or IgG-LDNG at NP:RBC 200:1 or 1000:1 
measured by fluorescent annexin V stain with flow cytometry. Tert-Butyl Peroxide was used as a positive control 
for induction of phosphatidylserine. Values are means (n = 3–4) ± SEM (***P < 0.001 vs naïve RBC).
www.nature.com/scientificreports/
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as 1000:1 did not affect the RBC deformability (EImax). Surprisingly, the adsorption of IgG-LDNGs resulted in a 
significant increase in RBC rigidity compared to naïve RBC in a dose-dependent manner; displaying a rightward 
shift in elongation index curves, resulting in a decrease in EImax values (Fig. 7a and b). In all cases, the SS1/2 values, 
reflecting the rate at which RBCs respond to stress, were not statistically different following NP adsorption for 
PSNP, LDNG, or IgG-LDNG at any of the investigated NP:RBC ratios.
We also evaluated the deformability of freshly isolated human RBCs from different individuals who have never 
traveled to malaria-affected areas. Unlike murine RBCs, PSNP adsorption on human RBCs did not affect the RBC 
deformability (Supplemental Fig. S8). The EImax at NP:RBC loading ratios as high as 1000:1 did not result in a right-
ward shift in the elongation index curves; Both EImax and SS1/2 values remained similar to those for naïve RBC. The 
adsorption of LDNGs onto human RBCs did not significantly affect deformability up to NP:RBC ratio of 1000:1.
Discussion and Conclusion
To be clinically useful, nanocarriers/nanoparticles must not induce severe adverse effects on RBCs at loadings 
necessary for therapeutic applications. This is particularly true for NPs and drug delivery technologies that 
intentionally interact with the RBC membrane. Previously, we and other labs observed that RBCs may serve as 
“super-carriers” for NPs, as non-covalent attachment of PSNP to murine RBCs markedly alters the biodistribu-
tion of the NP in a manner advantageous to treatment of many diseases. In these seminal studies, PSNPs were 
used as a representative NP to evaluate RBCs as cellular carriers for NP delivery. However, in our subsequent 
studies, it has been shown that bare PSNPs induce osmotic, mechanical, and oxidative hemolysis as well as RBC 
agglutination at PSNP:mRBC loading ratios 50:1 or greater48. While this as such is not a concern since PSNPs are 
simply a model particle and not a therapeutic vehicle, this observation brings up the question about engineering 
of particle properties to mitigate RBC toxicity. Agglutination is possibly due to the highly charged surface of 
PSNP as compare to LDNG; the more negatively charged PSNP surface may bridge RBCs in in suspension via 
electrostatic interactions.
Figure 7. The deformability of murine red blood cells with adsorbed nanoparticles. Elongation index vs shear 
stress plots of murine red blood cells after adsorption of PSNP, LDNG, and IgG-LDNG at NP:RBC loading 
ratios of 200:1 (a) and 1000:1 (b). Values are means (n = 3–5) ± SEM. (*P < 0.05; **P < 0.01; ***P < 0.001 vs 
naïve RBC).
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In our current work, we show that the adsorption of PSNP in high loadings has additional detrimental effects 
on RBCs including 1) promoting the exposure of phosphatidylserine (a marker for cell senescence) on the surface 
of RBCs and 2) increasing the rigidity of the RBC. PSNPs of both 200 nm and 300 nm diameter induced RBC 
agglutination at loading concentrations over PSNP:RBC of 50:1 and enhanced RBC sensitivity to osmotic and 
mechanical stress. We also show that some of the detrimental effects caused by bare PSNP can be circumvented 
by conjugating antibodies to the surface of the bare PSNP. This indicates that the observed results are due to the 
physicochemical properties of polystyrene; a terminal layer of IgG will change the surface charge and elasticity of 
the PSNP which. For example, the surface charge of IgG-PSNP is closer to neutral compared to PSNP, suggesting 
minimizing surface charge might prevent RBC agglutination and alter the interactions of PSNPs with the RBC 
membrane.
Since it is widely accepted that material properties of NPs influence their interactions with cells (e.g. attach-
ment, uptake, toxicity, and compatibility), studies focused on elucidating the effect of material properties on 
carrier RBCs will direct future translational efforts64. In the present study, we have taken these first steps towards 
translational efforts by utilizing biodegradable LDNGs as opposed to non-biodegradable PSNPs. LDNG was 
chosen as a second nanoparticle in this study because its properties contrast those of PSNPs in a number of 
critical ways; LDNGs are less rigid compared to PSNPs, the components of LDNGs are biodegradable and have 
demonstrated biocompatibility in previous work66, and the surface chemistry of LDNGs is characterized by 
strong hydrophilicity and minimal surface charge. Furthermore, there have been studies that have shown LDNGs, 
loaded with dexamethasone, can be useful for drug delivery66.
We have demonstrated that LDNGs do not induce NP-mediated damage (increased membrane stiffness, 
increased agglutination, etc) to RBCs at loadings at which PSNPs induce adverse effects. Importantly, this was 
observed for LDNGs even at NP:RBC loading ratios up to 2000:1. Key physicochemical differences between 
LDNGs and PSNPs are likely responsible for the observed differences in their RBC sensitization and compatibility; 
LDNGs with antibody conjugated to their surface, which still have a zeta potential close to neutral, also didn’t 
induce toxic effects on RBCs, further supporting the hypothesis that near neutral surface charge correlates with 
NP-RBC compatibility. Even though the mechanism of LDNG-RBC compatibility has not been fully elucidated, we 
believe that the composition and surface chemistry of NPs are major factors in their biocompatibility with RBCs.
For example, PSNPs are rigid and hydrophobic, non-responsive to aqueous environments, and have highly 
charged surfaces; PSNPs may alter the organization of RBC membrane phospholipids, leading to phosphatidyl-
serine exposure, resulting in loss of integrity, and possibly causing pore formation in the RBC membrane leading 
to lysis. However, the conjugation of antibody to the surface of the rigid PSNP might prevent the rigid material 
from directly interacting with the RBC membrane. On the other hand, LDNGs are soft, swellable, hydrophilic 
networks and wouldn’t cause these detrimental effects; The deformable surface of the LDNGs would facilitate flex-
ible contact points between the RBC and LDNG surfaces29 and the near-neutral surface charge of LDNGs is less 
likely to initiate electrostatic interactions that can lead to disruption of RBC membranes and/or surface proteins. 
Furthermore, hydrophilicity of the surface and internal hydrogel network of LDNGs allows the LDNGs to take on 
key properties of the fluid osmotic environment in which LDNG-RBC attachment, circulation, and delivery occur.
Although few, if any, harmful effects of LDNG attachment to RBCs were observed in vitro, further studies are 
necessary to justify the use of LDNGs in RBC drug delivery. In previous studies, LDNGs have been successful in 
delivering drugs, and RBCs have been used as carriers for NP delivery. However, additional toxicological studies 
should be performed to confirm biocompatibility of LDNGs with other cell types66. Future research utilizing car-
rier RBCs to deliver LDNGs will be focused on elucidating toxicological effects of the adsorbed LDNGs in vivo. 
In conclusion, we have extended our understanding of NP-RBC delivery systems by highlighting how the mate-
rial properties of NPs can be used to control interactions with the carrier RBC through limiting negative effects 
to the carrier cell. Although NPs were adsorbed onto isolated RBCs, and the NPs might interact with various 
components in the blood when delivered in vivo, these results illustrate the potential utility of LDNGs in treating 
diseases by delivery of a greater drug payload when adsorbed onto RBCs.
Materials and Methods
Ethics Statement. All animal studies were carried out in strict accordance with Guide for the Care and 
Use of Laboratory Animals as adopted by the National Institutes of Health, and approved by the University 
of Pennsylvania Institutional Animal Care and Use Committee (IACUC). All experiments were performed in 
accordance with relevant guidelines and regulations. Mice were anesthetized with ketamine/xylazine. All animals 
were euthanized by cervical dislocation and death was confirmed by cessation of heartbeat.
All studies involving human subjects were approved by the University of Pennsylvania Institutional Review 
Board. Written informed consent from donors was obtained for the use of blood samples in this study. Blood 
samples were destroyed after the study. Names and any personal information about individual participants were 
not taken.
Blood Collection. CJ7BL/6 J male mice were purchased from the Jackson Laboratory (Bar Harbor, ME). 
All mice were housed in a temperature- and humidity-controlled environment (18–23 °C with 40–60% humid-
ity under a 12-hour light-dark cycle) with ad libitum access to food (Labdiet 5010 autoclavable rodent diet, 
Brentwood, MO) and water.
Blood from CJ7BL/6 J mice was harvested at the University of Pennsylvania. Whole blood was collected 
in EDTA to prevent coagulation. Blood donation of human voluntary donors also occurred at the University 
of Pennsylvania. A volume of 4 mL of whole blood was collected in a vial containing ~3.2% Na citrate (BD 
Vacutainer). Blood was centrifuged at 1000 g for 10 min at 4 °C to remove plasma and buffy coat and isolate 
erythrocytes.
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Isolated erythrocytes (RBCs) were washed by adding ice cold 1× Dulbecco’s-Phosphate-Buffered-Saline 
(DPBS), pH 7.4, up to 12 mL total volume and pipetting gently up and down to mix buffer with RBC extensively. 
The RBC suspension was centrifuged again (500 g, 15 min, 4 °C) and the supernatant was discarded. This wash 
step was repeated a total of 3 times.
Synthesis of Lysozyme Dextran Nanogels. LDNGs were synthesized via a two-step heating process65. 
Briefly, dextran and lysozyme were dissolved in a 1:1 mol:mol ratio in water. The pH of the mixture was adjusted 
to ~7.1 and the mixture was lyophilized. The resulting powder was allowed to react at 60 °C at ~80% relative 
humidity for 24 h over saturated KBr solution. The reacted lysozyme and dextran was dissolved in water at 5 mg/
mL and the solution pH was adjusted to 10.7, prior to reaction for 30 min at 80 °C. The resulting LDNGs were 
stored at 4 °C.
Conjugation of IgG onto Nanoparticles. EDC carbodiimide crosslinker chemistry was used to con-
jugate rat IgG onto polystyrene beads Briefly, PSNP solutions were buffer exchanged with 50 mM MES pH 5.2. 
Sulfo-NHS was added to a concentration of 0.275 mg/mL and PSNP-Sulfo-NHS solutions were incubated for 
3 min. EDAC was then added to a final concentration of 0.1 mg/mL and the solution was incubated for 15 min. 
IgG was added at 200 IgG per bead and the solution was incubated for 4 h on a shaker at low speed. Thereafter, 
IgG-PS beads were spun down at 12,000 g and resuspended in PBS. IgG-PS were then sonicated at 30% amplitude 
3 times.
The attachment of IgG to LDNGs was performed as previously reported66. Briefly, unmodified LDNGs were 
oxidized by incubation with sodium periodate (2.5 mM) at room temperature for 3 days in the dark. IgG was then 
added to the LDNGs in DI water and the IgG-LDNG mixture was incubated at 4 °C overnight. Following the con-
jugation of IgG via amine-aldehyde bond, IgG-LDNGs were centrifuged at 16,000 g for 15 min and supernatant 
containing unbound IgG was removed. IgG-LDNG pellet was then re-suspended into PBS.
Nanoparticle Radiolabeling. Both PS beads and LDNGs were radiolabeled with 125I-IgG with the methods 
used above. Unmodified LDNGs and IgG itself were directly radiolabeled with 125I using Pierce iodination beads. 
Unmodified PSNP were radiolabeled with 3H conjugated oleic acid as previous described29.
Adsorption of Nanoparticles to RBCs. Briefly, murine or human RBCs were incubated with either 
unmodified or IgG-coated nanoparticles (NPs) (200 nm and 300 nm carboxylated polystyrene beads (PSNP) or 
268 nm lysozyme-dextran nanogels (LDNG)) at NP:RBC ratios of 50:1, 200:1, 1000:1, or 2000:1 for 1 h under 
constant rotation at 4 °C. NP:RBC solutions were washed with PBS three times at 100 g for 8 min to remove 
non-adsorbed NPs prior to experiments.
For direct comparison with other particles, such as IgG-PSNP at a NP:RBC ratio of 200:1, we used linear 
regression to estimate the value of the adsorption efficiency for PSNP:RBC at that ratio. The linear regression 
model used 4 data points over a range of NP:RBC ratios of 50:1 to 2000:1, yielding an r-squared value of 0.99 and 
an estimated adsorption efficiency of 24% for a PSNP:RBC ratio of 200:1.
The number of RBCs in 10% hematocrit solutions was determined based on theoretical RBC volume. The 
number concentrations of PSNPs in stock solutions were provided by the manufacturer. LDNG concentrations 
in stock solutions were set by using standardized mass concentrations of lysozyme and dextran during LDNG 
synthesis and drawing LDNGs used in the RBC studies from the original LDNG stocks as synthesized. After 
radiolabeling the NPs, the initial volume of NPs (either PSNPs or LDNGs) added to RBCs was chosen according 
to the desired NP:RBC loading ratio. The final quantity of NPs loaded on RBCs (and efficiency of NP load-
ing) was determined by tracing radioactivity on pelleted RBCs and comparing to initially introduced levels of 
NP-associated radioactivity.
RBC Osmotic Fragility. Osmotic fragility assay on freshly-obtained RBC and NP:RBC was performed as 
previously reported48. Briefly, washed RBC and NP:RBC suspensions were placed in salt concentrations ranging 
from 0 mM to 150 mM at 37 °C. NP:RBC or RBC suspensions, at a final concentration of 1% hematocrit, were 
then immediately centrifuged at 13,400 g for 4 min and the absorbance of the supernatant was recorded at 540 nm 
by SpectraMax M2 plate reader (Molecular Devices) as an indicator of hemoglobin release due to RBC lysis. 
Hemoglobin release following RBC submersion in water was taken as 100% RBC lysis.
RBC Fragility under low shear stress. Low shear stress fragility assay was performed on freshly-obtained 
washed RBCs. All RBC samples were subjected simultaneously to the same stress. RBC and NP:RBC suspensions 
of 1.0% hematocrit in DPBS were rotated (24 rpm) for different time periods at 37 °C. RBC and NP:RBC suspen-
sions were centrifuged at 13,400 g for 4 min, supernatants were obtained, and hemoglobin in the supernatant 
was immediately measured by absorbance at 540 nm with a SpectraMax M2 plate reader (Molecular Devices). 
Hemoglobin release following RBC submersion in water was taken as 100% RBC lysis.
RBC Oxidative Fragility under low shear stress. Freshly-obtained RBCs were subjected to hydrogen 
peroxide-induced lysis. Identical oxidative stress was simultaneously applied to all erythrocyte samples. 1.0% 
hematocrit suspensions of RBCs and NP:RBCs, with 3 mM H2O2 in DPBS, were rotated (24 rpm) for different 
time periods at 37 °C. Control samples were not subjected to H2O2 treatments. The hemoglobin released from the 
RBCs during rotation was measured, as was the free hemoglobin in the control samples, by 540 nm absorbance 
with a SpectraMax M2 plate reader (Molecular Devices). Hemoglobin release following RBC submersion in water 
was taken as 100% RBC lysis.
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RBC Phosphatidylserine. Phosphatidylserine exposure on RBCs was measured according to previously 
reported flow cytometry procedure based on the binding of Annexin V-Alexa FluorTM 488 (Invitrogen) to phos-
phatidylserine. Briefly, RBC and NP:RBC suspensions at 0.01% hematoocrit were incubated at room temperature 
with fluorescent annexin V in buffer containing 2 mM CaCl2 for 15 min. After incubation, an aliquot was aspi-
rated directly into the Accuri Flow Cytometer C6 (BD) for analysis. RBC populations were defined by forward 
and side scatter parameters. Results were expressed as percentages of phosphatidylserine-positive RBCs. Each 
experiment was repeated at least three times, and statistical analysis was performed.
RBC Deformability. RBC and NP:RBC deformability was measured by ektacytometry (Rheo Meditech, 
South Korea) operating at room temperature. Briefly, 25 µL of 10% hematocrit suspension of RBCs or RBC:NP 
was mixed with 675 µL of 5.5% (w/v) 360 kDa polyvinylpyrrolidone (Sigma Aldrich). RBC suspensions were 
placed into flow channels and subjected to shear stress varying from 0 Pa to 18 Pa. Ellipsoidal diffraction patterns 
generated by RBC suspensions under stress were recorded and relationship between applied stress and elongation 
of the diffraction index was analyzed. Modeled maximum elongation index (EImax) and half maximum shear 
stress (SS1/2) were determined. Each experiment was repeated at least three times.
Statistical Analysis. Results are expressed as mean ± SEM unless otherwise noted. Significant difference 
between means were determined by two tailed t-test. P < 0.05 was considered statistically significant.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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